Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193271
Status:
COMPLETED
Last Update Posted:
2011-05-03
First Post:
2005-09-12
Brief Title:
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Adjuvant Chemotherapy Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will evaluate the feasibility toxicity and efficacy of docetaxelestramustine as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy
Detailed Description:
Upon determination of eligibility patients will receive
Docetaxel Estramustine
Docetaxel Estramustine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IIT16165 | None | None | None |